Industry News
Pharmaceutical Industry News
Eli Lilly has made a six-year, $50…
Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to improve the prevention, detection and management of noncommunicable diseases.
PharmaForceIQ’s Derek Choy…
PharmaForceIQ’s Derek Choy explains how data, real-time signals, and optimizing for share of answer are reshaping how pharma brands engage HCPs and patients.
Following an FDA approval in…
Following an FDA approval in muscle-invasive bladder cancer patients who are eligible to receive cisplatin-based chemotherapy, AstraZeneca on Thursday reported positive phase 3 results for its Imfinzi, used alongside Padcev, in those who were cisplatin-ineligible.
With the FDA now rudderless…
With the FDA now rudderless following the revelation that commissioner Marty Makary, M.D., is stepping down, voices across biopharma have joined in support of the FDA’s former top drug regulator Richard Pazdur, M.D., as President
BMS and Hengrui signed a massive…
BMS and Hengrui signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal 2026. Daiichi Sankyo aims to be a global top-5 oncology player while expanding beyond antibody-drug
AI search is collapsing the health…
AI search is collapsing the health info funnel. Learn how GEO determines whether your brand is the answer—or invisible.
The framework would leverage…
The framework would leverage existing safety data on approved drugs to provide new options to patients with unmet medical needs, the FDA explained.
Generics juggernaut Sun Pharma is…
Generics juggernaut Sun Pharma is pulling one lot of a chemotherapy drug in the United States as the issue of particulate contamination crops up once again on the FDA’s recall register.
Taiwan’s Bora Group will shell…
Taiwan’s Bora Group will shell out up to $127.5 million to acquire the CDMO business and manufacturing operations from Maryland-based MacroGenics.
Purdue Pharma Is Gone. What Comes Next Could Be Worse.
The Purdue Pharma case is closed, but the opioid problem remains.
BeOne Medicines has entered the…
BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta.
How privacy-first data and…
How privacy-first data and data-driven TV are helping pharma brands cut waste and reach real patients.
Why siloed strategies fall short…
Why siloed strategies fall short and how integrated decision-making is reshaping pharmaceutical launches.
As President Trump lands in…
As President Trump lands in Beijing, one major industry is missing from his business delegation—pharma.
Meaningful involvement in MND…
Meaningful involvement in MND research ensures patient perspectives shape progress, making science relevant and compassionate.
The case for DTP is made. What…
The case for DTP is made. What separates programs that deliver from ones that stall? Gifthealth breaks down what it actually takes.
Under new CEO Kai Beckmann, Merck…
Under new CEO Kai Beckmann, Merck KGaA is emphasizing M&A to stock its early- to mid-stage pharma pipeline, the company said in reporting its first quarter results.
Takeda’s multiyear slim-down is…
Takeda's multiyear slim-down is expected to hit about 4,500 roles during the 2026 fiscal year, resulting in about 170 billion Japanese yen ($1.07 billion) in restructuring costs and some 100 billion yen ($633 million) in
The FDA has issued an untitled…
The FDA has issued an untitled letter to BeOne Medicines’ U.S. subsidiary over a TV commercial promoting its BTK blood cancer drug Brukinsa, saying the ad used “compelling and attention-grabbing visuals” that did not hold
Eli Lilly and Novo Nordisk are…
Eli Lilly and Novo Nordisk are building cases for their incretin drugs, both new and old, as attractive weight loss maintenance options and a potentially speedier option to shed pounds, respectively.